We are focused on the discovery, development and
commercialization of first-in-class treatments for
Leveraging the body’s
VBL’s clinical pipeline is based on two platform technologies that enhance natural physiologic and genetic regulatory elements.
Our lead candidate is VB-111, a gene-based biologic agent for solid tumor indications. VB-111 pivotal Phase 3 GLOBE trial in rGBM is ongoing under a special protocol assessment granted by the FDA.